Vogenx Inc (NASDAQ:VOGX) Stock Short Interest Jumps 93.6%

Vogenx Inc (NASDAQ:VOGX – Get Free Report) saw a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 74,122 shares, a growth of 93.6% from the October 15th total of 38,289 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average daily trading volume, of 80,725 shares, the days-to-cover ratio is presently 0.9 days.

Analyst Ratings Changes

A number of equities research analysts recently commented on VOGX shares. JonesTrading initiated coverage on shares of Vogenx in a report on Tuesday, September 1st. They set a “buy” rating and a $55.00 price objective on the stock. Wall Street Zen downgraded Vogenx from a “hold” rating to a “sell” rating in a research note on Saturday. Zacks Research upgraded Vogenx to a “hold” rating in a report on Monday, September 28th. Weiss Ratings began coverage on Vogenx in a research report on Monday, November 9th. They set a “sell (e-)” rating for the company. Finally, WBB Securities began coverage on Vogenx in a report on Wednesday, September 2nd. They set a “speculative buy” rating and a $42.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Vogenx currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

Read Our Latest Analysis on Vogenx

Vogenx Stock Down 13.7%

Shares of VOGX stock opened at $14.38 on Tuesday. The company has a fifty day moving average price of $21.68. Vogenx has a one year low of $12.61 and a one year high of $38.41.

Vogenx (NASDAQ:VOGX – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. As a group, equities research analysts predict that Vogenx will post -0.61 earnings per share for the current fiscal year.

Institutional Trading of Vogenx

An institutional investor recently bought a new stake in Vogenx stock. Goldman Sachs Group Inc. bought a new position in shares of Vogenx Inc (NASDAQ:VOGX – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 12,454 shares of the company’s stock, valued at approximately $284,000. Goldman Sachs Group Inc. owned about 0.08% of Vogenx at the end of the most recent quarter.

Vogenx Company Profile

(Get Free Report)

Vogenx Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc. is based in RALEIGH, NC.

Further Reading

Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.